Dr. Marchi is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1240 Lee St
Charlottesville, VA 22908Phone+1 434-924-9333Fax+1 434-244-7526
Education & Training
- New York Presbyterian Hospital (Columbia Campus)Fellowship, Hematology and Medical Oncology, 2015 - 2018
- Lincoln Medical and Mental Health CenterResidency, Internal Medicine, 2012 - 2015
- New York University School of MedicinePost-Doctoral Fellowship, 2009 - 2011
- Columbia University Vagelos College of Physicians and SurgeonsPost-Doctoral Fellowship, 2007 - 2009
- University of BolognaClass of 2002
Certifications & Licensure
- NY State Medical License 2015 - 2025
- VA State Medical License 2020 - 2024
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Randomized Phase IIB Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in PTCL Start of enrollment: 2021 Feb 19
Roles: Contact, Principal Investigator
Publications & Presentations
PubMed
- 91 citationsA phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphomaJennifer E Amengual, Renee Lichtenstein, Jennifer K. Lue, Ahmed Sawas, Changchun Deng
Blood. 2018-01-25 - 46 citationsThe rapidly changing landscape in mature T-cell lymphoma (MTCL) biology and management.Enrica Marchi, Owen A. O'Connor
CA. 2020-01-01 - 61 citationsFludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-ra...Pier Luigi Zinzani, Monica Tani, Alessandro Pulsoni, Marco Gobbi, Alessio Perotti
The Lancet. Oncology. 2008-04-01
Press Mentions
- UVA Cancer Center Receives $5.75 Million to Battle Rare Blood CancersAugust 4th, 2022
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: